Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer

ACS Guidelines for Cervical Cancer Self-Collected HPV Testing Now Included

Pirtobrutinib Matches Ibrutinib in BTK Inhibitor–Naive CLL

Benefit of Azacitidine Plus Venetoclax Confirmed in AML

Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL